Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

BusinesswireOct 23 20:30

S&P 500 Futures Fall In Premarket Trading; Range Resources, Mueller Industries Lead

Dow JonesOct 22 19:30

Sarepta a New Buy at Jefferies on Muscular Dystrophy Franchise, Pipeline

Seeking AlphaOct 22 00:53

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

BenzingaOct 21 21:01

Unveiling 15 Analyst Insights On Sarepta Therapeutics

BenzingaOct 21 20:00

RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $182

Futu NewsOct 21 19:31 · Ratings